New Step by Step Map For P-gb-IN-1
MI-CP151 was a section 1b randomised, double-blind, placebo managed, dose-escalation, multicentre analyze To judge multiple intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Main trial goals have been To guage the safety and tolerability of sifalimumab in dermatomyositis or polymyositis indiv